Eagle Bay Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

Eagle Bay Advisors’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-337	Closed	-$566	–	663
2024 Q4	$566	Hold	337	–	–	﹤0.01%	958
2024 Q3	$960	Hold	337	–	–	﹤0.01%	1291
2024 Q2	$789	Hold	337	–	–	﹤0.01%	945
2024 Q1	$991	Hold	337	–	–	﹤0.01%	928
2023 Q4	$1.01K	Hold	337	–	–	﹤0.01%	784
2023 Q3	$1.06K	Hold	337	–	–	﹤0.01%	801
2023 Q2	$1.3K	Hold	337	–	–	﹤0.01%	791
2023 Q1	$933	Hold	337	–	–	﹤0.01%	821
2022 Q4	$607	Hold	337	–	–	﹤0.01%	872
2022 Q3	$1K	Hold	337	–	–	﹤0.01%	848
2022 Q2	$907	Buy	+337	New	+$1.25K	﹤0.01%	925
2022 Q1	–	Sell	-337	Closed	-$2K	–	708
2021 Q4	$2K	Hold	337	–	–	﹤0.01%	922
2021 Q3	$2K	Buy	+337	New	+$2.69K	﹤0.01%	968

Other funds holding NAUT

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return

MVG

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

ACI

Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Eagle Bay Advisors's NAUT Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Nautilus Biotechnolgy (NAUT) in Q1 2025, closing a stake of 337 shares — an estimated $566 sold.

Eagle Bay Advisors first reported a position in NAUT in Q3 2021 and held it in 13 quarters. The position peaked at $2K in Q4 2021. 88 funds tracked by Wall St. Rank hold NAUT as of Q1 2025.

Eagle Bay Advisors reported no remaining Nautilus Biotechnolgy position as of Q1 2025 after selling out during the quarter.
Eagle Bay Advisors sold 337 Nautilus Biotechnolgy shares in Q1 2025, an estimated $566.
Eagle Bay Advisors first reported a position in Nautilus Biotechnolgy in Q3 2021 and held it in 13 quarters.
Eagle Bay Advisors's Nautilus Biotechnolgy position peaked at $2K in Q4 2021.
88 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.